Buchang Pharma, a Chinese traditional Chinese medicine patent-medicine maker, specializes in R&D, production and sale, reaching hi-tech and health fields.
Zhang Jiancang, Zhang Yubo, and Yang Hongjun acquire a 5% stake in Shandong Buchang Dingsheng Pharmaceutical Co., Ltd. The transaction involves purchasing the stake from Shandong Buchang Pharmaceuticals Co., Ltd. and Xie Jihui for CNY 0.07 million. The deal formalizes their investment in the pharmaceutical company.
Shandong Buchang Pharmaceuticals reports first-quarter 2026 revenue of **CNY 2.58 billion**, down from **CNY 2.78 billion** in the same period last year. The company’s sales figures match its reported revenue, reflecting a year-over-year decline in financial performance. No additional operational details or segment-specific breakdowns are provided in the earnings update.
Shandong Buchang Pharmaceuticals plans to increase capital for one of its units and invest in a medical technology company. The move aims to strengthen its position in the pharmaceutical and medical technology sectors. No specific details on the investment amount or the target firm are provided.
Buchang Pharma is increasing its ownership stake in the Tianyin-Buchang Alliance joint venture. The update follows ongoing discussions between Tianyin Pharmaceutical and Buchang Pharma regarding the partnership structure. The move aims to further solidify their collaborative efforts in pharmaceutical development.